Aker Christopher Ray 4
4 · Regulus Therapeutics Inc. · Filed Jan 31, 2025
Insider Transaction Report
Form 4
Aker Christopher Ray
Sr. VP & General Counsel
Transactions
- Award
Stock Option (Right to Buy)
2025-01-30+487,500→ 487,500 totalExercise: $1.00Exp: 2035-01-29→ Common Stock (487,500 underlying)
Footnotes (1)
- [F1]The stock option commenced vesting on January 1, 2025 and will vest ratably on a monthly basis over a 48 month period subject to the reporting person's continuous service to Regulus through each such vesting date.